In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

“Novo Nordisk is deeply concerned about the proliferation of unapproved compounded ‘semaglutide’ and the risks they pose to patients. No one should have to compromise their health due to ...

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 billion ...

No one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients. Novo Nordisk responded to the use ...

The drugmaker Novo Nordisk can meet present and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame ... “There is no clear commercial rationale for these actions.” ...